{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:16:10Z","timestamp":1792858570797,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"20","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2025,7,10]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>More than 30% of patients with pancreatic cancer are unresectable because of the local extension with a median overall survival (OS) of &lt;1 year. Combination of fluorouracil (FU), oxaliplatin, and irinotecan (FOLFIRINOX) is superior to gemcitabine in the treatment of metastatic pancreatic cancer, but standard of care remains gemcitabine in locally advanced pancreatic cancer (LAPC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>\n              Patients with histologically proven LAPC not suitable for surgery, Eastern Cooperative Oncology Group WHO performance status (PS) \u22641 were eligible. Random assignment was stratified by center, tumor localization (pancreas head yes\/no), WHO PS (0\n              <jats:italic toggle=\"yes\">v<\/jats:italic>\n              1), and age (\u226460 years\n              <jats:italic toggle=\"yes\">v<\/jats:italic>\n              &gt;60 years). Patients received FOLFIRINOX or gemcitabine for 6 months. The primary end point was progression-free survival (PFS). Main secondary end points were OS, time to treatment failure, quality of life, and safety. One hundred seventy patients (142 events) were needed to detect an increase of 3 months in PFS with 80% power (log-rank test, 5% two-sided \u03b1).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>\n              One hundred seventy one patients age 35-84 years were included and followed for a maximum of 5 years. With a median follow-up of 59.6 months (95% CI, 42.3 to not reached), 168 events were observed and the median PFS was 9.7 months (95% CI, 7.0 to 11.7) with FOLFIRINOX versus 7.7 months (95% CI, 6.2 to 9.2) with gemcitabine, hazard ratio (HR), 0.7 (95% CI, 0.5 to 1.0),\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              = .04. The median OS was 15.7 months (95% CI, 11.9 to 20.4) in the FOLFIRINOX group versus 15.4 months (95% CI, 11.7 to 18.6) in the gemcitabine group, HR, 1.02 (95% CI, 0.73 to 1.43),\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              = .95.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Results confirm that FOLFIRINOX improves PFS significantly compared with gemcitabine and is well tolerated in LAPC. No significant difference in OS was observed between both groups.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/jco-24-02210","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T19:59:41Z","timestamp":1747425581000},"page":"2255-2264","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":29,"title":["PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct02539537","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-7449","authenticated-orcid":true,"given":"Michel","family":"Ducreux","sequence":"first","affiliation":[{"name":"Gustave Roussy Cancer Center, Tumor Cells Dynamics, INSERM U1279, Universit\u00e9 Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Desgrippes","sequence":"additional","affiliation":[{"name":"Hepato-Gastroenterology and Digestive Oncology Department, Centre Hospitalier de Saint Malo, Saint Malo, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Oncology, H\u00f4pital Europ\u00e9en, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Di Fiore","sequence":"additional","affiliation":[{"name":"Gastroenterology, CHU H\u00f4pitaux de Rouen-Charles Nicolle, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8344-1762","authenticated-orcid":true,"given":"Rosine","family":"Guimbaud","sequence":"additional","affiliation":[{"name":"Digestive Oncology, Centre Hospitalier Rangueil, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Evesque","sequence":"additional","affiliation":[{"name":"Medical Oncology, Centre Antoine Lacassagne, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4337-286X","authenticated-orcid":true,"given":"Jean-Baptiste","family":"Bachet","sequence":"additional","affiliation":[{"name":"Sorbonne University, Hepato-Gastroenterology Department, Groupe Hospitalier Piti\u00e9 Salpetri\u00e8re, APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Vanelslander","sequence":"additional","affiliation":[{"name":"Gastroenterology, H\u00f4pital Saint Claude, Saint Quentin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-0212","authenticated-orcid":true,"given":"Thierry","family":"Lecomte","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology and Digestive Oncology Departement, H\u00f4pital Trousseau, Chambray-Les-Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1211-2758","authenticated-orcid":false,"given":"Olivier","family":"Capitain","sequence":"additional","affiliation":[{"name":"Medical Oncology, Institut de Canc\u00e9rologie de l'Ouest\u2014Centre Paul Papin, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Parzy","sequence":"additional","affiliation":[{"name":"Digestive Pathology, Centre Francois Baclesse, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Bolliet","sequence":"additional","affiliation":[{"name":"Gastroenterology, H\u00f4pitaux Civils de Colmar, Colmar, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Luc","family":"Etienne","sequence":"additional","affiliation":[{"name":"Medical Oncology, H\u00f4pital Priv\u00e9 des C\u00f4tes d\u2019Armor, Plerin sur Mer, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Forestier","sequence":"additional","affiliation":[{"name":"Medical Oncology, H\u00f4pital Edouard Herriot, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"El Hajbi","sequence":"additional","affiliation":[{"name":"Urology and Digestive Oncology, Centre Oscar Lambret, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Bignon","sequence":"additional","affiliation":[{"name":"Gastroenterology, CHU C\u00f4te de Nacre, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Lebrun-Ly","sequence":"additional","affiliation":[{"name":"Medical Oncology, CHU de Limoges, Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"De Sousa Carvalho","sequence":"additional","affiliation":[{"name":"R&amp;D, UNICANCER, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8303-3315","authenticated-orcid":true,"given":"Matthieu","family":"Texier","sequence":"additional","affiliation":[{"name":"Biostatistics, Gustave Roussy Institut de Canc\u00e9rologie, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3743","authenticated-orcid":true,"given":"Olivier","family":"Bouche","sequence":"additional","affiliation":[{"name":"Digestive Oncology Department, CHU Reims, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_3_10_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.07.005"},{"key":"e_1_3_10_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01752-3"},{"key":"e_1_3_10_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0155"},{"key":"e_1_3_10_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809775"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2017.11.011"},{"key":"e_1_3_10_8_2","volume-title":"Pancreatic Adenocarcinoma","author":"National Comprehensive Cancer Network Clinical Practice in Oncology (NCCN Guidelines)","unstructured":"National Comprehensive Cancer Network Clinical Practice in Oncology (NCCN Guidelines): Pancreatic Adenocarcinoma. Version 1.2024. https:\/\/www.nccn.org"},{"key":"e_1_3_10_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02233"},{"key":"e_1_3_10_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0901557"},{"key":"e_1_3_10_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.009"},{"key":"e_1_3_10_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/80.10.751"},{"key":"e_1_3_10_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851201)56:11<2563::AID-CNCR2820561104>3.0.CO;2-0"},{"key":"e_1_3_10_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn281"},{"key":"e_1_3_10_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4324"},{"key":"e_1_3_10_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv295"},{"key":"e_1_3_10_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.08.008"},{"key":"e_1_3_10_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"e_1_3_10_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_3_10_20_2","volume-title":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","year":"2006","unstructured":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD, Cancer Therapy Evaluation Program, 2006"},{"key":"e_1_3_10_21_2","volume-title":"EORTC QLQ-C30 Scoring Manual","author":"Fayers PAN","year":"2001","unstructured":"Fayers PAN, Bjordal K, Groenvold M, et al: EORTC QLQ-C30 Scoring Manual. Brussels, Belgium, European Organisation for Research and Treatment of Cancer, 2001"},{"key":"e_1_3_10_22_2","volume-title":"EORTC QLQ-C 30 Reference Values","author":"Fayers PWS","year":"1998","unstructured":"Fayers PWS, Curran D: EORTC QLQ-C 30 Reference Values. Brussels, Belgium, European Organisation for Research and Treatment of Cancer, 1998"},{"key":"e_1_3_10_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00172-8"},{"key":"e_1_3_10_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.12.014"},{"key":"e_1_3_10_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.02.023"},{"key":"e_1_3_10_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.675"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-24-02210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T21:59:49Z","timestamp":1751925589000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-24-02210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":25,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,7,10]]}},"alternative-id":["10.1200\/JCO-24-02210"],"URL":"https:\/\/doi.org\/10.1200\/jco-24-02210","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"2024-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}